Signos, a metabolic health platform, has announced a successful Series B funding round, raising $20 million. The funding will be used to address the obesity and metabolic health crisis in the United States. The company’s platform utilizes an artificial intelligence (AI) engine and continuous glucose monitor (CGM) to provide real-time data and recommendations for healthy weight management. With over 96 million Americans being prediabetic and an estimated 1 billion people projected to have diabetes by 2050, glucose management and weight gain are ongoing challenges.
Signos currently offers a metabolic-led solution to reverse prediabetes and assist individuals on their weight loss journey. The platform allows users to log their food intake and exercise, enabling the AI system to learn how their metabolism responds to different foods and fitness patterns. Based on an individual’s unique metabolic profile, Signos provides data-driven personalized recommendations. By focusing on factors such as sleep, stress, exercise, and diet, the platform aims to help users make healthier choices.
The recent funding round was led by Cheyenne Ventures and GV (Google Ventures), with additional funding from Dexcom Ventures and Samsung Next. The funding will enable Signos to expand its core team and platform, as well as conduct further research on metabolic health.
The CEO of Signos, Sharam Fouladgar-Mercer, emphasizes the importance of glucose visibility, tracking, and AI-driven suggestions in helping individuals make informed decisions for better health. Jay Fulcher, Managing Partner of Cheyenne Ventures, believes that Signos’ data-driven approach to weight and overall health has the potential to create lasting outcomes for individuals.
Signos was launched in 2018 and combines continuous glucose information with an AI-enhanced app to provide personalized recommendations for healthy and sustained weight loss. With the majority of the American adult population being overweight or obese, Signos aims to help individuals act on their body’s unique glucose responses and kickstart a healthier life. The company was founded by a team with expertise in data and AI applications for improving health outcomes.
Overall, Signos’ Series B funding round of $20 million will provide the company with the necessary resources to address the obesity and metabolic health crisis in the US, expand its team and platform, and conduct further research on metabolic health.
